retatrutide type 2 diabetes More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Phase Retatrutide Phase 2: Type 2

Medical weight loss works best when it is properly supervised

Unlike current single (GLP-1) and dual (GLP-1/GIP) agonist compounds like Semaglutide and Tirzepatide , Retatrutide is a triple agonist compound targeting three hormone receptors instead of only one or two: GLP-1 (glucagon-like peptide-1) GIP (glucose-dependent insulinotropic polypeptide) GCG (glucagon receptor) According to a landmark clinical trial published in the New England Journal of Medicine , Retatrutide demonstrated significant weight reduction, up to 30%, in participants over a 48-week period, highlighting its potential as a next-generation metabolic peptide

The result significant caloric restriction is exactly what drives the weight loss

Originally developed for managing type 2 diabetes, these medications are now making headlines for their broader impact on weight, metabolic health and cardiovascular health

For many individuals, weight loss has been a life-long battle often characterised by yo-yo weight gain

As its predicted GLP-1 use will continue to rise in OSA patients, a common topic in discussions, according to Peters, is how GLP-1s might affect the use of other sleep apnea therapies, like CPAP, oral appliances, and hypoglossal nerve stimulation